Doxoform and daunoform: Anthracycline-formaldehyde conjugates toxic to resistant tumor cells

Journal of Medicinal Chemistry

Volumn 40, Issue 16, 1997, Pages 2452-2461

  Fenick, David J ^a   Taatjes, Dylan J ^a   Koch, Tad H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTOCHROME P450 REDUCTASE; DAUNOFORM; DAUNORUBICIN; DOXOFORM; DOXORUBICIN; FORMALDEHYDE; OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; HYDROLYSIS; LIPOPHILICITY; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; TUMOR CELL CULTURE;

ALKYLATION; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAUNORUBICIN; DIMERIZATION; DNA; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FORMALDEHYDE; HUMANS; HYDROLYSIS; MASS SPECTROMETRY; MODELS, CHEMICAL; OXAZOLES; TUMOR CELLS, CULTURED;

EID: 0030737770     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970237e     Document Type: Article

References (55)

1. Young, R. C.; Ozols, R. F.; Myers, C. E. Medical Progress: The anthracycline antineoplastic drugs. New Engl. J. Med. 1981, 305, 139-153.
2. Volm, M.; Mattern, J.; Samsel, B. Overexpression of P-glyco-protein and glutathione S-transferase-π in resistant non-small cell lung carcinomas of smokers. Br. J. Cancer 1991, 64, 700-704.
3. Giai, M.; Biglia, N.; Sismondi, P. Chemoresistance in breast tumors. Eur. J. Gynaecol. Oncol. 1991, 12, 359-373.
4. Black, S. M.; Wolf, C. R. The role of glutathione-dependent enzymes in drug resistance. Pharmacol. Ther. 1991, 51, 139-154.
5. Serafino, A.; Sinibaldi-Vallebona, P.; Gaudiano, G.; Koch, T. H.; Rasi, G.; Ravagnan, G. Int. J. Cancer 1997, 57, submitted for publication.
6. Blair, S. L.; Heerdt, P.; Sachar, S.; Abolhoda, A.; Hochwald, S.; Cheng, H.; Burt, M. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res. 1997, 57, 152-155.
7. Sinha, B. K.; Mimnaugh, E. G. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radical Biol. Med. 1990, 8, 567-581.
8. Chaires, J. B.; Satyanarayana, S.; Suh, D.; Fokt, I.; Przewloka, T.; Priebe, W. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry 1996, 35, 2047-2053.
9. Egorin, M. J.; Hildebrand, R. C.; Cimono, E. F.; Bachur, N. R. Cytofluorescence localization of Adriamycin and Daunorubicin. Cancer Res. 1974, 34, 2243-2245.
10. Coley, H. M.; Amos, W. B.; Twintyman, P. R.; Workman, P. Examination by laser confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br. J. Cancer 1993, 67, 1316-1323.
11. Wang, A. H.-J.; Ughetto, G.; Quigley, G. J.; Rich, A. Interaction between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2 Å resolution. Biochemistry 1987, 26, 1152-1163.
12. Frederick, C. A.; Williams, L. D.; Ughetto, G.; Vander Marel, G. A.; Van Boom, J.; Rich, A.; Wang, A. H. J. Structural comparison of anticancer drug-DNA complexes: Adriamycin and Daunomycin. Biochemistry 1990, 29, 2538-2549.
13. Pan, S.; Pedersen, L.; Bachur, N. R. Comparative flavoprotein catalysis of anthracycline antibiotic reductive cleavage and oxygen consumption. Mol. Pharmacol. 1981, 19, 184-186.
14. Schreiber, J.; Mottley, C.; Sinha, B. H.; Kalyanaraman, B.; Mason, R. One-electron reduction of Daunomycin, daunomycinone, and 7-deoxydaunomycinone by the xanthine/xanthine oxidase system: detection of semiquinone free radicals by electron spin resonance. J. Am. Chem. Soc. 1987, 109, 348-351.
15. Kappus, H. Overview of enzyme systems involved in bioreduction of drugs and in redox cycling. Biochem. Pharmacol. 1986, 35, 1-6.
16. Lown, W. J.; Chen, J. A.; Plambeck, J. A.; Acton, E. M. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem. Pharmacol. 1982, 31, 575-581.
17. Doroshow, J. H. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983, 43, 4543-4551.
18. Sinha, B. K. Free radicals in anticancer drug pharmacology. Chem. Biol. Interact. 1989, 69, 293-317.
19. Kleyer, D.; Koch, T. H. Mechanistic investigation of reduction of Daunomycin and 7-deoxydaunomycinone with bi(3,5,5-trimethyl-2-oxomorpholin-3-yl). J. Am. Chem. Soc. 1984, 106, 2380-2387.
20. Abdella, B. R. J.; Fisher, J. A chemical perspective on the anthracycline antitumor antibiotics. Environ. Health Perspect. 1985, 64, 3-18.
21. Gaudiano, G.; Resing, K.; Koch, T. H. Reaction of anthracycline antitumor drugs with reduced glutathione. Formation of aglycon conjugates. J. Am. Chem. Soc. 1994, 116, 6537-6544.
22. Moore, H. W.; Czerniak, R. Naturally occurring quinones as potential bioreductive alkylating agents. Med. Res. Rev. 1981, 1, 249-280.
23. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-375.
24. Tritton, T. R. Cell surface actions of Adriamycin. Pharmacol. Ther. 1991, 49, 293-301.
25. Cullinane, C.; van Rosmalen, A.; Phillips, D. R. Does adriamycin induce interstrand cross-links in DNA? Biochemistry 1994, 33, 4632-4638.
26. Cullinane, C.; Cutts, M. S.; van Rosmalen, A.; Phillips, D. R. Formation of Adriamycin-DNA adducts in vitro. Nucleic Acids Res. 1994, 22, 2296-2303.
27. van Rosmalen, A.; Cullinane, C.; Cutts, S. M.; Phillips, D. R. Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res. 1995, 23, 42-50.
28. Cutts, S. M.; Phillips, D. R. Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin. Nucleic Acids Res. 1995, 23, 2450-2456.
29. Cutts, S. M.; Parsons, P. G.; Sturm, R. A.; Phillips, D. R. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Biol. Chem. 1996, 271, 5422-5429.
30. Skladanowski, A.; Konopa, J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem. Pharmacol. 1994, 47, 2279-2287.
31. Skladanowski, A.; Konopa, J. Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem. Pharmacol. 1994, 47, 2269-2278.
32. Skladanowski, A.; Konopa, J. Adriamycin and Daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 1993, 46, 375-382.
33. Taatjes, D. J.; Gaudiano, G.; Resing, K.; Koch, T. H. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 1996, 39, 4135-4138.
34. Taatjes, D. J.; Gaudiano, G.; Resing, K.; Koch, T. A redox pathway leading to the alkylation of DNA by the anthracycline, anti-tumor drugs, adrimaycin and daunomycin. J. Med. Chem. 1997, 40, 1276-1286.
35. Taatjes, D. J.; Gaudiano, G.; Koch, T. H. Production of formaldehyde and DNA-adriamycin or -daunomycin adducts, initiated through redox chemistry of DTT/iron, xanthine oxidase/NADH/ iron, or glutathione/iron. Chem. Res. Toxicol. 1997, in press.
36. Wang, A. H. J.; Gao, Y. G.; Liaw, Y. C.; Li, Y. k. Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 1991, 30, 3812-3815.
37. Lambert, J. B.; Majchrzak, M. W. Ring-chain tautomerism in 1,3-diaza and 1,3-oxaza heterocycles. J. Am. Chem. Soc. 1980, 102, 3588-3591.
38. Barkworth, P. M. R.; Crabb, T. A. Compounds with bridgehead nitrogens. Part 41. The reaction between trans-2-aminocycloalkanols and formaldehyde. J. Chem. Soc. Perkin Trans. II 1982, 91-94.
39. Cowan, K. H.; Batist, G.; Tulpule, A.; Sinha, B. K.; Myers, C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 9328-9332.
40. Myers, C. E.; Gianni, L.; Simone, C. B.; Klecker, R.; Greene, R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 1982, 21, 1707-1712.
41. Lampidis, T. J.; Kolonias, D.; Podona, T.; Israel, M.; Safa, A. R.; Lothstein, L.; Savaraj, N.; Tapiero, H.; Priebe, W. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry 1997, 36, 2679-2685.
42. Batist, G.; Tulpule, A.; Sinha, B. K.; Katki, A. G.; Myers, C. E.; Cowan, K. H. Overexpression of a novel anionic glutathione transferase in multi-drug-resistant human breast cancer cells. J. Biol. Chem. 1986, 261, 15544-15549.
43. Gudas, J. M.; Nguyen, H.; Li, T.; Sadzewicz, L.; Robey, R.; Wosikowski, K.; Cowan, K. H. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis 1996, 17, 1417-1427.
44. Hartwell, L. H.; Kastan, M. B. Cell cycle control and cancer. Science 1994, 266, 1821-1828.
45. Linn, S. C.; Honkoop, A. H.; Hoekman, K.; Valk, P. v. d.; Pinedo, H. M.; Giaccone, G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br. J. Cancer 1996, 74, 63-68.
46. Acton, E. M.; Tong, G. L.; Mosher, C. W.; Wolgemuth, R. L. Intensely Potent Morpholinyl Anthracyclines. J. Med. Chem. 1984, 27, 638-645.
47. Cullinane, C.; Phillips, D. R. Thermal stability of DNA adducts induced by cyanomorpholinoadriamycin in vitro. Nucleic Acids Res. 1993, 21, 1857-1862.
48. Uchida, T.; Imoto, M.; Takahashi, Y.; Odagawa, A.; Sawa, T.; Tatsuta, K.; Naganawa, H.; Hamada, M.; Takeuchi, T.; Umezawa, H. New potent anthracyclines, barminomycins I and II. J. Antibiot. 1988, 41, 404-408.
49. Ikeda, D.; Ajito, K.; Kondo, S.; Takeuchi, T. Synthesis of 3″-dehydro-4-O-methylbarminomycin II having an eight-membered acetal-azomethine ring. Chem. Lett. 1990, 1431-1432.
50. Nagy, A.; Armatis, P.; Schally, A. V. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2464-2469.
51. Zwelling, L. A.; Altschuler, E.; Cherif, A.; Farquhar, D. N-(5,5-Diacetoxypentyl)doxorubicin: A novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res. 1991, 51, 6704-6707.
52. Cherif, A.; Farquhar, D. N-(5,5-Diacetoxypent-1-yl)doxorubicin: A New Intensely Potent Doxorubicin Analogue. J. Med. Chem. 1992, 35, 3208-3214.
53. Leng, F.; Savkur, R.; Fokt, I.; Przewloka, T.; Priebe, W.; Chaires, J. B. Base specific and regiospecific chemical cross-linking of Daunorubicin to DNA. J. Am. Chem. Soc. 1996, 118, 4731-4738.
54. Gilles, R. J.; Didier, N.; Denton, M. Determination of cell number in monolayer cultures. Anal. Biochem. 1986, 159, 109-113.
55. Reile, H.; Birnböck, F.; Bernhardt, G. T.; Spruss, H. S. Computerized determination of growth kinetic curves and doubling times from cells in microcultures. Anal. Biochem. 1990, 187, 262-267.